Study of JS004 plus toripalimab for Hodgkin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have classical Hodgkin lymphoma that has come back or not responded to your last treatment.
- You have already tried a PD-1 or PD-L1 immunotherapy drug and it stopped working (refractory).
- You are able to do daily activities with little or no help (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan (like a CT scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests a new combination treatment for a type of lymphoma (B-cell non-Hodgkin's lymphoma) that has a protein called CD20 on its cells. It may be an option if you have not received certain previous therapies and your lymphoma is measurable, to see if the combination can help control the disease.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.